News
Hosted on MSN1mon
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s UnswayedMerck & Co., Inc. (MRK ... Co. for an investigational oral drug for heart disease called HRS-5346. Under the agreement, Merck will have the exclusive rights to develop, manufacture, and ...
Hosted on MSN1mon
Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights DealUnder the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug ... a Moderate Buy based on 11 Buys ...
that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback